Do you have questions about getting a COVID-19 vaccine?

If you are on treatment for multiple sclerosis (MS) and have questions about COVID-19 or the COVID-19 vaccines, contact your healthcare provider for answers and guidance. It is very important to continue taking your MS medicine as prescribed and to follow your healthcare provider’s treatment directions.

For additional information, there are helpful online resources that address the question of whether people with MS should get a COVID-19 vaccine, including the National MS Society and the The Consortium of Multiple Sclerosis Centers. To learn more about your vaccination options, talk with your healthcare provider.

US-REB-00324 04/2021

UNDERSTANDING TREATMENT GOALS

In order to choose the treatment that’s right for you, it’s important to understand a little about your type of multiple sclerosis (MS) and what to expect from your medication.

Rebif® (interferon beta-1a) is a treatment for relapsing forms of multiple sclerosis (RMS), the most common type of MS.

Graphic of a NEURON (NERVE CELL) with text – Myelin sheath

What is RMS?

RMS is an autoimmune disorder in which the body attacks itself. Specifically, the immune system attacks the coating (the myelin sheath) on the nerves in the brain, spinal cord, and eye area, which can cause scarring and prevent the nerves from communicating correctly. This communication breakdown can lead to symptoms of MS, which can vary in severity, and may lead to permanent damage. 

 

n
n

Relapses (flare-ups) and remissions

RMS is characterized by relapses and remissions.

  • Relapses—also called flare-ups, attacks, or exacerbations—occur when 1 or more RMS symptoms (such as numbness or blurred vision) appears or worsens, and remains for at least 24 hours

  • During the remission phase, the symptoms may partially or completely go away

In the chart below, you can see that a person’s abilities may not fully recover following a relapse.

 

Graph showing Relapses and Remission with Disability on the Y axis and Time on the X axis

 

  • Note that being in remission does not mean you no longer need your treatment. It is important to continue Rebif® as prescribed by your healthcare provider

  • Rebif® does not treat the symptoms of RMS, but has been proven in a clinical trial to help reduce the frequency of relapses. See study results showing reduced relapse rates with Rebif®

 

n
n

Understanding lesions

When the body’s immune system attacks the covering of the nerves, it leaves scars called lesions. Technically, these are referred to as “sclerotic lesions,” which is where MS gets its name. Healthcare providers look for these lesions using magnetic resonance imaging (MRI) to help them diagnose RMS and select an appropriate treatment for their patients. Once a patient is taking a treatment, healthcare providers use MRI scans to judge how well that treatment is working. Rebif® (interferon beta-1a) has been proven in a clinical trial to reduce the number of new and enlarging MRI brain lesions—this is another one of the important goals of treating RMS.

 

How do healthcare providers look for lesions inside the body?

They use MRI scans.

 

Image of two MRI brain scans. The brain on the left has text that says – T1-weighted Gd-enhanced scan. The brain on the right has text that says – T2-weighted scan

 

MRI machines use magnets to see inside the brain and spinal cord to find lesions. There are 2 types of MRI scans usually used for people living with RMS. A T1-weighted gadolinium-enhanced (T1-Gd+) MRI supplies information about current disease activity by highlighting areas of active inflammation and permanent nerve damage, whereas a T2-weighted MRI image provides information about total disease burden (that is, both old and new lesions).

 

n
n

ABOUT DISABILITY PROGRESSION

Over time, the accumulation of relapses and incomplete healing can lead to a worsening of movement, walking ability, cognition, vision, and any other symptom MS can cause. This is called disability progression. Because everybody’s MS is different, everyone’s disease progresses at a different rate.

Measuring disability progression

Disability progression is measured using the Expanded Disability Status Scale (EDSS). This is one tool healthcare providers use to measure disability progression, especially in the clinical trial settings.

 

The EDSS and disability progression

 

Graphic of four people at different stages of disability from Fully Ambulatory to Impaired Walking Ability

 

Here’s how it works: After examining and speaking with the patient, a healthcare provider assigns a number based on their level of disability. That score can be compared at a later date to measure any progression in the patient’s disability.

People who have EDSS scores from 1 to 4 are fully ambulatory, meaning they can still walk. For people with scores 5 or higher, their ability to walk will be increasingly impaired. In clinical trials, comparing scores over time can help researchers judge how well a treatment helps to slow disability progression—an important treatment goal.

 

n
n

Healthcare providers and people living with RMS continue to choose Rebif®

There are many reasons to consider Rebif® (interferon beta-1a), including:

  • Efficacy results
  • Safety profile
  • Support from MS LifeLines®

 

Side effects

Rebif® can cause serious side effects. Tell your healthcare provider right away if you have any of the following while taking Rebif®: behavioral health problems including depression and suicidal thoughts, liver problems or worsening of liver problems including liver failure, serious allergic and skin reactions, injection site problems, blood problems, or seizures.

 

Infection icon

Rebif® in the body

See how Rebif® is thought to work in treating RMS.

Question mark icon

Have questions about RMS or treatment with Rebif®?

Find answers to commonly asked questions.


IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information

Before beginning treatment, you should discuss the potential benefits and risks associated with Rebif with your healthcare provider.

Rebif can cause serious side effects. Tell your healthcare provider right away if you have any of the symptoms listed below while taking Rebif.

  • Behavioral health problems including depression and suicidal thoughts. You may have mood problems including depression (feeling hopeless or feeling bad about yourself), and thoughts of hurting yourself or suicide
  • Liver problems or worsening of liver problems including liver failure. Symptoms may include nausea, loss of appetite, tiredness, dark colored urine and pale stools, yellowing of your skin or the white part of your eye, bleeding more easily than normal, confusion, and sleepiness. During your treatment with Rebif you will need to see your healthcare provider regularly and have regular blood tests to check for side effects
  • Serious allergic and skin reactions. Symptoms may include itching, swelling of your face, eyes, lips, tongue or throat, trouble breathing, anxiousness, feeling faint, skin rash, hives, sores in your mouth, or skin blisters and peels
  • Injection site problems. Symptoms at the injection site may include redness, pain, swelling, color changes (blue or black), and drainage of fluid
  • Blood problems. Rebif can affect your bone marrow and cause low red and white blood cell and platelet counts. In some people, these blood cell counts may fall to dangerously low levels. If your blood cell counts become very low, you can get infections and problems with bleeding and bruising. Your healthcare provider may ask you to have regular blood tests to check for blood problems
  • Seizures. Some people have had seizures while taking Rebif

Rebif will not cure your MS but may decrease the number of flare-ups of the disease and slow the occurrence of some of the physical disability that is common in people with MS.

Do not take Rebif if you are allergic to interferon beta, human albumin, or any of the ingredients in Rebif.

Before you take Rebif, tell your healthcare provider if you have or have had any of the following conditions:

  • mental illness, including depression and suicidal behavior
  • liver problems, bleeding problems or blood clots, low blood cell counts, seizures (epilepsy), or thyroid problems
  • you drink alcohol
  • you are pregnant or plan to become pregnant. It is not known if Rebif will harm your unborn baby
  • you are breastfeeding or plan to breastfeed. Rebif may pass into your breastmilk. Talk with your healthcare provider about the best way to feed your baby if you take Rebif

Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

The most common side effects of Rebif include:

  • flu-like symptoms. You may have flu-like symptoms when you first start taking Rebif. You may be able to manage these flu-like symptoms by taking over-the-counter pain and fever reducers. For many people, these symptoms lessen or go away over time. Symptoms may include muscle aches, fever, tiredness, and chills
  • stomach pain
  • change in liver blood tests

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Rebif. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. 

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

Rebif® (interferon beta-1a) is a prescription medicine used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.